These results suggest that the anti-RCC effects of IL-22 are directly mediated by regulation of the STAT1 signaling pathways and G2/M cell cycle arrest rather than by induction of apoptosis or inflammatory cytokines. The gene discussed is IL22; the disease is renal cell carcinoma.